Compound derived from baby spinach is promising in treatment of atopic dermatitis

A recent study found that a novel compound, derived from baby spinach leaves, has yielded improvements in efficacy in adults with atopic dermatitis.

Charles Lynde, MD, of Lynde Dermatology, Probity Medical Research, and the department of medicine at the University of Toronto, and colleagues wrote: “Atopic dermatitis is a common skin disorder for which there remains an unmet need for topical pharmacotherapies that are safe and effective. PUR 0110 cream (Thykamine, Devonian Health Group) is a novel investigational complex derived from organic baby spinach leaves that contains thylakoid membrane segments of various lengths that are concentrated and stabilized into a solid powder form.”

In the study, conducted at 13 sites in Canada between November 2018 and June 2020, Lynde and colleagues assessed 0.05%, 0.1% and 0.25% doses of the cream in a cohort of 162 patients with mild to moderate AD.

“PUR 0110 cream 0.1% demonstrated rapid improvement in signs and symptoms of atopic dermatitis,” the researchers concluded. “This observation, along with its favorable safety and tolerability profile, could make it a useful therapeutic option for the treatment of atopic dermatitis.”


Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber